Citadel Advisors
ZBIO

Citadel Advisors’s Zenas BioPharma ZBIO Stock Holding History

Citadel Advisors’s Portfolio ZBIO Stock Details ZBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.97M Buy
195,780
+128,910
+193% +$2.56M ﹤0.01% 4731
2026
Q1 		$1.31M Buy
66,870
+42,411
+173% +$952K ﹤0.01% 7049
2025
Q4 		$888K Buy
+24,459
New +$804K ﹤0.01% 7649
2025
Q3 		– Sell
-293,785
Closed -$2.85M – 14443
2025
Q2 		$2.85M Buy
+293,785
New +$2.86M ﹤0.01% 5061
2025
Q1 		– Sell
-82,624
Closed -$677K – 15823
2024
Q4 		$677K Sell
82,624
-11,698
-12% -$182K ﹤0.01% 7899
2024
Q3 		$1.6M Buy
+94,322
New +$1.7M ﹤0.01% 5932

Other funds holding ZBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
RPSM
Royalty Pharma Sub-Manager New York $242M AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Citadel Advisors's ZBIO Position: Q2 2026 in Review

Citadel Advisors increased its Zenas BioPharma (ZBIO) stake by 193% in Q2 2026, buying an estimated $2.56M and bringing the position to 195,780 shares worth $4.97M. The position accounts for ﹤0.01% of the portfolio, ranked #4731.

Citadel Advisors first reported a position in ZBIO in Q3 2024 and has held it in 6 quarters since. 144 funds tracked by Wall St. Rank hold ZBIO as of Q2 2026.

  • Citadel Advisors held 195,780 shares of Zenas BioPharma worth $4.97M as of Q2 2026.
  • Citadel Advisors bought 128,910 Zenas BioPharma shares in Q2 2026, an estimated $2.56M.
  • Zenas BioPharma made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #4731 holding.
  • Citadel Advisors first reported a position in Zenas BioPharma in Q3 2024 and has held it in 6 quarters since.
  • 144 funds tracked by Wall St. Rank held Zenas BioPharma as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.